Clinical Pharmacology and Therapeutics
A Textbook of Clinical Pharmacology and ... - clinicalevidence
A Textbook of Clinical Pharmacology and ... - clinicalevidence
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
170 ANTI-INFLAMMATORY DRUGS AND THE TREATMENT OF ARTHRITIS<br />
inflammatory process in inflammatory arthritis. Their mechanisms<br />
are generally poorly understood. They are used in<br />
patients with progressive disease. Response (though unpredictable)<br />
is usually maximal in four to ten weeks. Unlike<br />
NSAIDs, DMARDs reduce inflammatory markers (historically,<br />
it was this effect that led to them being referred to as ‘diseasemodifying’).<br />
It is difficult to prove that a drug influences the<br />
natural history of a relapsing/remitting <strong>and</strong> unpredictably progressing<br />
disease, such as rheumatoid arthritis, but immunosuppressants<br />
retard the radiological progression of bony<br />
erosions. DMARDs are toxic, necessitating careful patient monitoring,<br />
<strong>and</strong> are best used by physicians experienced in rheumatology.<br />
Rheumatologists use them earlier than in the past, with<br />
close monitoring for toxicity, with the patient fully informed<br />
about toxic, as well as desired, effects. This is especially important<br />
since many of these drugs are licensed for quite different<br />
indications to arthritis. In terms of efficacy, methotrexate, gold,<br />
D-penicillamine, azathioprine <strong>and</strong> sulfasalazine are similar,<br />
<strong>and</strong> are all more potent than hydroxychloroquine. Methotrexate<br />
(Chapter 48) is better tolerated than the other DMARDs, <strong>and</strong> is<br />
usually the first choice. Sulfasalazine (Chapter 34) is the second<br />
choice. Alternative DMARDs, <strong>and</strong> some of their adverse effects,<br />
are summarized in Table 26.1.<br />
GOLD SALTS<br />
Use<br />
Gold was originally introduced to treat tuberculosis. Although<br />
ineffective, it was found to have antirheumatic properties <strong>and</strong><br />
has been used to treat patients with rheumatoid arthritis since<br />
the 1920s. Sodium aurothiomalate is administered weekly by<br />
deep intramuscular injection. About 75% of patients improve,<br />
with a reduction in joint swelling, disappearance of rheumatoid<br />
nodules <strong>and</strong> a fall in C-reactive protein (CRP) levels. Urine<br />
must be tested for protein <strong>and</strong> full blood count (with platelet<br />
count <strong>and</strong> differential white cell count) performed before each<br />
injection. Auranofin is an oral gold preparation with less toxicity,<br />
but less efficacy than aurothiomalate. Treatment should<br />
be stopped if there is no response within six months.<br />
Mechanism of action<br />
The precise mechanism of gold salts is unknown. Several<br />
effects could contribute. Gold–albumin complexes are phagocytosed<br />
by macrophages <strong>and</strong> polymorphonuclear leukocytes<br />
<strong>and</strong> concentrated in their lysosomes, where gold inhibits lysosomal<br />
enzymes that have been implicated in causing joint<br />
damage. Gold binds to sulphhydryl groups <strong>and</strong> inhibits<br />
sulphhydryl–disulphide interchange in immunoglobulin <strong>and</strong><br />
complement, which could influence immune processes.<br />
Adverse effects<br />
Adverse effects are common <strong>and</strong> severe:<br />
• Rashes are an indication to stop treatment, as they can<br />
progress to exfoliation.<br />
• Photosensitive eruptions <strong>and</strong> urticaria are often preceded<br />
by itching.<br />
• Glomerular injury can cause nephrotic syndrome.<br />
Treatment must be withheld if more than a trace of<br />
proteinuria is present, <strong>and</strong> should not be resumed until<br />
the urine is protein free.<br />
• Blood dyscrasias (e.g. neutropenia) can develop rapidly.<br />
Table 26.1: Disease-modifying antirheumatic drugs (DMARDs)<br />
Drug Adverse effects Comments<br />
Immunosuppressants: Blood dyscrasias, carcinogenesis, Methotrexate is usually the first-choice<br />
azathioprine, methotrexate, opportunistic infection, alopecia, DMARD<br />
ciclosporin<br />
nausea; methotrexate also causes<br />
mucositis <strong>and</strong> cirrhosis; ciclosporin<br />
causes nephrotoxicity, hypertension<br />
<strong>and</strong> hyperkalaemia<br />
Sulfasalazine Blood dyscrasias, nausea, rashes, First introduced for arthritis, now used<br />
colours urine/tears orange<br />
mainly in inflammatory bowel disease<br />
(Chapter 34)<br />
Gold salts Rashes, nephrotic syndrome, Oral preparation (auranofin) more<br />
blood dyscrasias, stomatitis,<br />
convenient, less toxic, but less effective than<br />
diarrhoea<br />
intramuscular aurothiomalate<br />
Penicillamine<br />
Blood dyscrasias, proteinuria,<br />
urticaria<br />
Antimalarials: chloroquine, Retinopathy, nausea, diarrhoea, See Chapter 47<br />
hydroxychloroquine<br />
rashes, pigmentation of palate,<br />
bleaching of hair